Shares of Argenx (ARGX) have moved sharply lower in late morning trading and are down $14.12, or 2.5%, to $546.02 as of the time of this alert as traders circulate a posting that outlines drug product(s) with potential signals of serious risks/new safety information by the FDA based on a review of the FAERS system for January to March of this year. Vyvgart Hytrulo is listed as having “severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy” as a potential signas of a serious risks/new safety information and the posting states the FDA is “evaluating the need for regulatory action.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx announces plan to advance clinical development of ARGX-119
- Argenx’s Efgartigimod Study: A Promising Step for ITP Treatment
- Promising Growth Prospects for Argenx Se’s Vyvgart in CIDP and gMG Treatment Drive Buy Rating
- Argenx Gains European Approval for Novel CIDP Treatment
- Argenx price target lowered to EUR 650 from EUR 715 at Morgan Stanley